• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

BerGenBio

Selective AXL inhibitors

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | COVID-19
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
    • Expanded access policy
  • Media Centre
    • News
    • Events
    • COVID-19 Media Pack
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Careers
  • Contact
Home  /  2021

Year: 2021

2021202020192018201720162015

Radium Podcast interview with BerGenBio CEO Richard Godfrey, hosted by RADFORSK

February 17, 2021

Bergen, Norway, 17 February 2021 - In this Radium podcast interview with RADFORSK, BerGenBio CEO Richard Godfrey…

Read More

BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020

February 10, 2021

Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for…

Read More

SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO’S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS

February 8, 2021

Bergen, Norway, 8th February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020

January 29, 2021

· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…

Read More

BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS

January 27, 2021

Bergen, Norway, 27 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020

January 13, 2021

· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…

Read More
  • Go to page 1
  • Go to page 2
  • NEXT

Primary Sidebar

  • Media Centre
  • News
  • Events
  • COVID-19 Media Pack
  • Media Contacts

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Job Applicant Privacy Notice
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219 688

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs